William P. McEvoy III - 11 Nov 2025 Form 3 Insider Report for CYPHERPUNK TECHNOLOGIES INC. (LPTX)

Footnote F1

On October 6, 2025, Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.) (the "Company") entered into a securities purchase agreement (the "Securities Purchase Agreement") for the private placement of an aggregate of (i) 15,212,311 shares of Company common stock, par value $0.001 per share ("Common Stock"), at an offering price of $ 0.52064 per share, (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 80,768,504 shares of Common Stock (the "Pre-Funded Warrant Shares") at an offering price of $0.51964 per Pre-Funded Warrant, exercisable at the exercise price of $0.001 per Pre-Funded Warrant Share, and (iii) common warrants (the "Common Warrants") to purchase up to an aggregate of 71,985,605 shares of Common Stock (the "Common Warrant Shares"), exercisable at the exercise price of $0.5335 per Common Warrant Share (the "Private Placement"). The Private Placement closed October 8, 2025. (Continued in following footnote).

Footnote F2

(Continued from prior footnote) In connection with the Private Placement, Winklevoss Treasury Investments, LLC, a Delaware limited liability company ("WTI") acquired an aggregate of (i) 8,283,761 shares of Common Stock, (ii) Pre-Funded Warrants to purchase up to an aggregate of 75,448,618 Pre-Funded Warrant Shares, and (iii) Common Warrants to purchase up to an aggregate of 62,799,284 Common Warrant Shares (later reduced to 57,182,378 pursuant to the Assignment (defined below) (collectively, the "WTI Securities"), subject to beneficial ownership thresholds prohibiting beneficial ownership (as calculated in accordance with Section 13(d) of the Securities Exchange Act of 1933, as amended, and the rules and regulations promulgated thereunder) in excess of 19.99% of the issued and outstanding shares of Common Stock after giving effect to the Private Placement (the "Beneficial Ownership Limitation"), as may be adjusted downward from time to time. (Continued in following footnote).

Footnote F3

(Continued from prior footnote) Pursuant to information provided by WTI, the WTI Entities have assigned 5,616,906 of the 62,799,284 Common Warrants (the "Assignment"), reducing their reported beneficial ownership of the Common Warrants to 57,182,378.

Footnote F4

The WTI Securities are held by Winklevoss Capital Fund, LLC, a Delaware limited liability company, ("WCF"), WTI, Winklevoss Capital Management, LLC, a Delaware limited liability company ("WCM"), Mr. Tyler Howard Winklevoss ("Tyler Winklevoss"), and Mr. Cameron Howard Winklevoss ("Cameron Winklevoss" and, together with WCF, WTI, WCM and Tyler Winklevoss, the "WTI Entities"). Tyler Winklevoss and Cameron Winklevoss are the co-founders and managers of WCM. WCM is the manager of WCF, and WTI is a wholly owned subsidiary of WCF. (Continued in following footnote).

Footnote F5

(Continued from prior footnote) Mr. William McEvoy is the manager of WTI and Vice President of WCM. Mr. McEvoy disclaims beneficial ownership of the WTI Securities held by the WTI Entities, except to the extent of his pecuniary interest therein, if any. Mr. McEvoy was appointed to the Company's board of directors November 11, 2025, in connection with the Lead Investor Agreement, dated October 6, 2025, by and between the Company and WTI, as Lead Investor.

Footnote F6

Reflects Common Shares acquired pursuant to the Private Placement and consists of 8,283,761 shares of Common Stock held by the WTI Entities.

Footnote F7

Reflects Prefunded Warrants acquired pursuant to the Private Placement and consists of 75,448,618 Prefunded Warrants held by the WTI Entities, each exercisable for one share of Common Stock at the exercise price of $0.001 per Pre-Funded Warrant Share. The Pre-Funded Warrants are exercisable as of their date of issuance, however may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise would exceed the Beneficial Ownership Limitation. The Pre-Funded Warrants are exercisable in cash or by means of a cashless exercise and will not expire until the date such Pre-Funded Warrants are fully exercised. Each Pre-Funded Warrant is subject to appropriate adjustment.

Footnote F8

Reflects Common Warrants acquired pursuant to the Private Placement, as adjusted by the Assignment, and consists of 57,182,378 Common Warrants held by the WTI Entities, each exercisable for one share of Common Stock at the exercise price of $.5335 per Common Warrant Share. Subject to the terms of the Waiver and Modification Agreement, dated November 19, 2025, by and between the Company and WTI, the Common Warrants are exercisable as of their date of issuance, however may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise would exceed the Beneficial Ownership Limitation. The Common Warrants are exercisable in cash or by means of a cashless exercise and will not expire until the tenth anniversary of their date of issuance. Each Common Warrant is subject to appropriate adjustment.